Page 25 - Synlogic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FinancialContent fully hosted finance channel

Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory - Synlogic to provide bioprocess and manufacturing in joint effort to engineer novel investigational medicines to address battle fatigue - News provided by Share this article Share this article CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, has been recognized by the Air Force Research Laboratory (AFRL) as a Biotechn...

Press release content from Business Wire. The AP news staff was not involved in its creation. PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors January 29, 2021 GMT PureTech announced the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors. Dr. Chowrira has served as PureTech’s President and Chief of Business and Strategy since March 2017. (Photo: Business Wire) PureTech announced the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors. Dr. Chowrira has served as PureTech’s President and...

  PureTech Adds Bharatt Chowrira, PureTech's President and Chief of Business and Strategy, to Board of Directors     PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announces the appointment of Bharatt Chowrira, Ph.D., J.D., to its Board of Directors as an executive director. Dr. Chowrira has served as PureTech's President and Chief of Business and Strategy since March 2017 and...

Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine. The companies have also inked a long-ter...